# ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

> **NCT00161070** · PHASE4 · COMPLETED · sponsor: **UMC Utrecht** · enrollment: 4500 (—)

## Conditions studied

- Brain Ischemia
- Transient Ischemic Attack
- Arteriosclerosis

## Interventions

- **DRUG:** anticoagulation
- **DRUG:** aspirin and dipyridamole
- **DRUG:** aspirin alone

## Key facts

- **NCT ID:** NCT00161070
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 4500 (—)
- **Last updated:** 2007-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161070, "ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00161070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*